The study and its comparison
RE-ENERGIZE randomized 1,209 patients with severe burns to enteral glutamine or placebo; 1,200 were analyzed. Treatment began early after admission and continued according to the study’s recovery and time limits. [1]
Median time to discharge alive was forty days with glutamine and thirty-eight with placebo, without a significant difference. Six-month mortality also did not significantly differ. The analysis accounted for death as a competing event. [1]
What the finding establishes
A discharge endpoint must distinguish recovery from death rather than treating both as a short hospital stay. These findings concern severely injured hospitalized patients, not ordinary dietary glutamine intake. The US Department of Defense and CIHR funded the trial; complete conflicts were not established from the abstract. A metabolic rationale alone did not establish clinical benefit. [1]
A hypothetical distinction
Imagine two patients leave hospital early for very different reasons. An alive-discharge analysis must account for that distinction.
| Detail | Interpretation |
|---|---|
| Measured outcome | Keep the endpoint specific |
| Study preparation | Not every retail product |
| Remaining uncertainty | Not resolved by a mechanism |
Sources for this article
- A Randomized Trial of Enteral Glutamine for Treatment of Burn Injuries.
Source consulted: 2026-09-19. This is a reference resource, not a claim that we conducted the studies or tested a product.